Abbott Consent Decree Costs Escalate With Failed FDA QSR Inspection
This article was originally published in The Gray Sheet
Executive Summary
Costs related to Abbott's FDA consent decree could approach $1 bil. in lost revenue alone following a failed follow-up inspection of the company's Lake County, Illinois diagnostic manufacturing operations